+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Steatohepatitis"

From
Nonalcoholic Steatohepatitis (NASH): Update Bulletin - Product Thumbnail Image

Nonalcoholic Steatohepatitis (NASH): Update Bulletin

  • Newsletter
  • April 2024
  • Global
From
Disruptive Innovations Fueling Improved NASH Management - Product Thumbnail Image

Disruptive Innovations Fueling Improved NASH Management

  • Report
  • March 2020
  • 48 Pages
  • Global
From
Breakthroughs in Non-Alcoholic Steatohepatitis Management - Product Thumbnail Image

Breakthroughs in Non-Alcoholic Steatohepatitis Management

  • Report
  • March 2019
  • 46 Pages
  • Global
From
Competitor Landscape: Non-alcoholic Steatohepatitis (NASH) - Product Thumbnail Image

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

  • Report
  • November 2018
  • 52 Pages
  • Global
From
Signaling Pathways in Liver Diseases. Edition No. 3 - Product Thumbnail Image

Signaling Pathways in Liver Diseases. Edition No. 3

  • Book
  • October 2015
  • 520 Pages
  • 18 Results (Page 1 of 1)
Loading Indicator

Steatohepatitis is a type of liver disease that is characterized by the accumulation of fat in the liver, inflammation, and damage to the liver cells. It is a common form of liver disease, and is often associated with obesity, diabetes, and alcohol abuse. It can lead to cirrhosis, liver failure, and even death. Treatment for steatohepatitis includes lifestyle changes, such as weight loss, exercise, and a healthy diet, as well as medications to reduce inflammation and improve liver function. The steatohepatitis market is a growing segment of the hepatology market, as the prevalence of steatohepatitis is increasing due to the rise in obesity and diabetes. Companies in this market are focused on developing treatments and therapies to improve the quality of life of patients with steatohepatitis. Examples of companies in this market include Gilead Sciences, AbbVie, Bristol-Myers Squibb, Merck, and Novartis. Show Less Read more